Table 1 Characteristics of study subjects
Variable | n (%) | |
|---|---|---|
Age, yr | Median (range) | 53 (28–82) |
Histologic subtype | ||
Ductal, NOS | 181 (92.8) | |
Lobular | 4 (2.1) | |
Micropapillary | 9 (4.6) | |
Solid papillary with invasion | 1 (0.5) | |
Histologic grade | ||
I | 2 (1.0) | |
II | 94 (48.2) | |
III | 99 (50.8) | |
ER status | ||
ER+ | 183 (93.8) | |
ER- | 12 (6.2) | |
PR status | ||
PR+ | 160 (82.1) | |
PR- | 35 (17.9) | |
HER2 status | ||
IHC status | ||
1+ | 10 (5.1) | |
2+ | 185 (94.9) | |
Dual-probe ISH status | ||
± | 195 (100.0) | |
Polysomy 17 | ||
Yes | 137 (70.3) | |
No | 58 (29.7) | |
Ki-67 | ||
<20% | 49 (25.1) | |
≥ 20% | 146 (74.9) | |
TNM stage | ||
T (Primary tumour) | ||
T1 | 93 (47.7) | |
T2 | 98 (50.3) | |
T3 | 1 (0.5) | |
T4 | 3 (1.5) | |
N (Regional lymph nodes) | ||
N0 | 104 (53.3) | |
N1 | 57 (29.2) | |
N2 | 19 (9.8) | |
N3 | 15 (7.7) | |
M (Distant metastasis) | ||
M0 | 192 (98.5) | |
M1 | 3 (1.5) | |
Treatment | ||
Chemotherapy | 159 (81.5) | |
Radiotherapy | 89 (45.6) | |
Hormonal therapy | 123 (63.1) | |
Trastuzumab | 17 (8.7) | |